Steven Cohen Clovis Oncology, Inc. Call Options Transaction History

Point72 Asset Management, L.P.

1 transactions

Quarter	Operation	Price Per call	calls change	calls Held	SEC Form
Q4 2017 Feb 14, 2018	BUY	$57.69 - $84.58 $15.5 Million - $22.7 Million	268,000	268,000 $18.2 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.